What the FDA labels say about taking them together
Anagrelide and fluvoxamine
Anagrelide's FDA label of April 8, 2026 names fluvoxamine in its drug interactions section; the fluvoxamine labels PlainMeds reads (2) do not name anagrelide. The anagrelide label: “Drugs that inhibit CYP1A2 could increase the exposure of AGRYLIN.”
Check it at the source: the anagrelide FDA label on DailyMed (effective April 8, 2026, Takeda Pharmaceuticals America, Inc.); the fluvoxamine FDA label on DailyMed (effective June 27, 2026, Zydus Pharmaceuticals USA Inc.).
What does the anagrelide label say about fluvoxamine?
Anagrelide label, drug interactionsDrugs that inhibit CYP1A2 (e.g., fluvoxamine, ciprofloxacin) could increase the exposure of AGRYLIN.
Source: FDA drug label (Agrylin), Takeda Pharmaceuticals America, Inc., effective April 8, 2026 (SPL set cb960074-99c1-4a73-941f-f0644a7ec219), via openFDA; the full label on DailyMed
What does the fluvoxamine label say about anagrelide?
Fluvoxamine's label (effective June 27, 2026) and its 1 other brand-application label do not name anagrelide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Fluvoxamine maleate extended-release), Zydus Pharmaceuticals USA Inc., effective June 27, 2026 (SPL set 6c71d4f6-54b5-4d3a-8d2f-b7773c92c32e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Anagrelide | Fluvoxamine | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.729 per capsule 0.5 mg capsule | $4.08 per capsule 100 mg capsule |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once